期刊文献+

肝癌抗原肽SLIVHLNEV免疫原性研究

Immunogenicity of the Hepatocellar Carcinoma Antigenic Peptide SLIVHLNEV
原文传递
导出
摘要 肿瘤细胞抗原肽SLIVHLNEV可以与MHC-I类分子结合,由T细胞表位识别,激活细胞毒性T细胞(CTL),为肝癌免疫治疗开辟了新领域。文章通过软件DNAstar-protean与Syfpeithi分析,确定抗原肽的抗原表位。然后抗原肽刺激树突细胞,通过检测CD80,CD86的表达,观察抗原肽诱导树突细胞成熟的情况。将负载抗原肽的树突细胞与T细胞的混合淋巴细胞反应(MLR),MTT检测T细胞增殖的情况,确定最佳抗原肽浓度与最佳刺效比。以最佳抗原肽浓度与最佳刺效比刺激T淋巴细胞分化,测定T细胞表面CD8、CD4表达情况。结果表明抗原肽SLIVHLNEV不含B淋巴细胞抗原表位,而为HLA_A*02∶01型T淋巴细胞表位抗原,并可以刺激H2-Db表位,经树突细胞(APC)递呈,刺激T细胞分化为CTL,发挥细胞免疫作用。 The tumor antigenic peptide SLIVHLNEV which can be bound to MHC class I,recongnized by T lymphocytes and futher to activate the cytotoxic T cells(CTL),opened up a new field in tumor immunotherapy.In this paper,the epitope of antigenic peptide was analyzed by the software DNAstar-protean and SYFPEITHI.Then the dendritic cells were stimulated by the antigen peptide,and the expression of CD80 and CD86 was detected to investigate the antigenic peptide-induced maturation of dendritic cell.T cells were co-cultured with dendritic cells stimulated by antigenic peptides in the mixed lymphocyte reaction(MLR),and the proliferation of T cells was analyzed by MTT to determine the optimal concentration of the peptide and the best ratio of T cells to dendritic cells.Then,at the optimal concentration and ratio obtained above,the differentiation of T lymphocyte was stimulated and the expression level of CD8 and CD4 on the T cell surface was determined.The results showed that the antigen peptide SLIVHLNEV contains HLA_A * 02∶ 01 T lymphocyte antigen epitope while none of the B lymphocyte antigen epitopes is included,and it can stimulate the H2-DB epitope,too.The expression level of CD80 and CD86 of the dendritic cells gets rised after stimulation by the antigen peptide.It proves that the tumor antigenic peptide SLIVHLNEV can stimulate the DCs' maturation.In MLR experiment,the antigen peptide induced the T cells proliferation after the presentation by dendritic cells(APC).The optimal concentration of peptide is 50 μmol / L and the best ratio of T cells to dendritic cells is 51.Under this condition,T cells' differentiation is mainly into CTL,which is the role of cell-mediated immunity.
出处 《药物生物技术》 CAS 2013年第4期301-305,共5页 Pharmaceutical Biotechnology
关键词 肿瘤抗原肽 抗原表位预测 APC 树突成熟 MLR CTL Tumor antigenic peptide Epitope prediction Antigen presenting cell Dendritic cell maturation Mixed lymphocyte reaction CTL response
  • 相关文献

参考文献11

  • 1Amadori D, Milandri C, Comella G, et al. A phase 1/17 trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer[ J ]. Eur J Cancer,2011, 1 0.
  • 2Melief CJ. Van der Burg SH. lmmunotherapy of established (per) malignant disease by synthetic long peptide vaccines[ J]. Nat Rev Cartcer,2008,8(5 ) :351.
  • 3Van der Bruggen P, Traversari C, Chomez P, et al. A geneencod- ing an antigen recognized by cytolytic T lymphoeytes on a human melanoma [J ]. Science, 1991,254 ( 5038 ) : 1643.
  • 4Sahoo R, Babu VC, Harini VV, et al. Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options [ J] Onkologie,2011,34 (7) : 356.
  • 5Wang H,Su X,Zhang P,et al. Recombinant heat shock protein 65 carrying PADRE and HBV epitopes activates dendritic cells and elicits HBV-specific CTL responses [ J ]. Vaccine, 2011, 29 (12) :2328.
  • 6郭爱林,隋延仿.肝癌抗原肽的分离、纯化、鉴定及抗原肽疫苗的研究[D].第四军医大学,2001,6.
  • 7曲萍,隋延仿.负载人肝细胞癌肿瘤排斥抗原肽的人树突状细胞疫苗抗肿瘤作用的实验研究[D].第四军医大学,2001.
  • 8Young-Ik Son, Shin-ichi Egawa, Tomohide Tatsumi, et al. A novelbulk-culture method for generating mature dendritic cells from mouse bone marrow cells [J]. J Immunol Meth,2002,262,145.
  • 9刘铮,代继宏,符州,冯琳琳.小鼠骨髓源树突状细胞体外诱导培养及初步鉴定[J].生物学杂志,2011,28(2):25-27. 被引量:4
  • 10吴亚红,高艳锋,祁元明.肿瘤抗原细胞毒性T淋巴细胞表位鉴定和多肽疫苗的研究进展[J].郑州大学学报(医学版),2011,46(5):657-660. 被引量:7

二级参考文献29

  • 1熊菲,程茜.树突状细胞培养技术的研究进展[J].国外医学(临床生物化学与检验学分册),2005,26(4):238-240. 被引量:8
  • 2Tan HT, Low J, Lim SG, et al. Serum autoantibodies as biomarkers for early cancer detection[ J ]. FEBS J, 2009, 276 (23) :6880.
  • 3Naz RK, Dabir P. Peptide vaccines against cancer, infec- tious diseases, and conception [ J ]. Front Biosci, 2007, 12:1833.
  • 4Kawakami Y, Cancer treatment by comprehensive regula- tion of anti-tumor immune network [ J ]. Nihon Rinsho, 2010, 68(6) :1094.
  • 5Khazaie K, Bonertz A, Beckhove P. Current developments with peptide-based human tumor vaccines [ J ]. Curr Opin Oncol, 2009, 21(6):524.
  • 6Beck A, Klinguer-Hamour C, Bussat MC, et al. Peptides as tools and drugs for immunotherapies [ J ]. J Pept Sci, 2007, 13(9) :588.
  • 7Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy [ J ]. Cancer Sci, 2009, 100(11) :2014.
  • 8Ahneida LG, Sakabe N J, deOliveira AR, et al. CTdata- base : a knowledge-base of high-throughput and curated da- ta on cancer-testis antigens[ J ]. Nucleic Acids Res, 2009, 37 ( Database issue) : D816.
  • 9Bao L, Dunham K, Lucas K. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to fa- cilitate cytotoxic T lymphocyte-mediated tumor cell killing [ J ]. Cancer Immunol Immunother ,2011 May 28 [ Epub a- head of print ].
  • 10Reuschenbach M, Waterboer T, Wallin KL, et al. Char- acterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-as-sociated cancers[J]. Int J Cancer, 2008, 123(11) :2626.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部